Dr. Fidler Discusses Osimertinib in EGFR-Mutated Lung Cancer
In Partnership With:
Mary Jo Fidler, MD, associate professor, medical oncology, hematology, internal medicine, Rush University Medical Center, discusses osimertinib (Tagrisso) in patients with EGFR T790M-positive non–small cell lung cancer.
Mary Jo Fidler, MD, associate professor, medical oncology, hematology, internal medicine, Rush University Medical Center, discusses osimertinib (Tagrisso) in patients with EGFR T790M-positive non—small cell lung cancer.
In a phase III trial, there was a clear benefit of osimertinib when compared with standard frontline platinum doublet chemotherapy in patients who progressed on a first-generation TKI.
Related Videos
Related Content
